Valued EpiGenetic Glycemic ImprovEments Through Weight Loss

NACompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

July 29, 2020

Study Completion Date

December 2, 2020

Conditions
ObesityPre-diabetes
Interventions
BEHAVIORAL

Weight Loss Group

All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack

BEHAVIORAL

Delayed Weight Loss

18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program

Trial Locations (1)

27157

Wake Forest Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

Medifast, Inc.

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02869659 - Valued EpiGenetic Glycemic ImprovEments Through Weight Loss | Biotech Hunter | Biotech Hunter